Denali Therapeutics (DNLI) Operating Leases (2019 - 2026)

Denali Therapeutics (DNLI) has 8 years of Operating Leases data on file, last reported at $24.7 million in Q1 2026.

• Quarterly Operating Leases fell 42.65% year-over-year to $24.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.7 million (down 42.65% YoY) and the FY2025 annual result came in at $27.2 million, down 25.8% from the prior year.
• Operating Leases declined to $24.7 million in Q1 2026 per DNLI's latest filing, from $27.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $62.7 million in Q1 2022 and bottomed at $24.7 million in Q1 2026.
• The 5-year median for Operating Leases is $46.9 million (2023), against an average of $44.4 million.
• The widest annual swing landed in 2024, when Operating Leases grew 0.0%; it then sank 42.65% in 2026.
• Tracing DNLI's Operating Leases over 5 years: stood at $53.0 million in 2022, then dropped by 15.18% to $45.0 million in 2023, then declined by 18.47% to $36.7 million in 2024, then retreated by 25.8% to $27.2 million in 2025, then retreated by 9.3% to $24.7 million in 2026.
• Per Business Quant, the three latest DNLI Operating Leases figures stand at $24.7 million (Q1 2026), $27.2 million (Q4 2025), and $29.7 million (Q3 2025).

Peer Comparison